Rosen Law investigates Disc Medicine after FDA issues CRL
Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. following a Complete Response Letter from the FDA for its bitopertin program. The regulatory rejection on February 13, 2026, caused a 22% drop in the company's stock price. The firm is preparing a class action lawsuit to recover investor losses.
*this image is generated using AI for illustrative purposes only.
Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) regarding allegations that the company may have issued materially misleading business information. The investigation focuses on the impact of a regulatory decision that caused a significant decline in the company's stock price.
On February 13, 2026, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Disc Medicine regarding its bitopertin program. The FDA stated it could not approve the company's new drug application (NDA) due to uncertainties that would require additional evidence. Following this announcement, Disc Medicine's stock price fell 22% on February 13, 2026.
The law firm is preparing a class action lawsuit seeking recovery of investor losses. Shareholders who purchased Disc Medicine securities may be entitled to compensation through a contingency fee arrangement without any out-of-pocket fees or costs.
Investors who wish to join the prospective class action can contact the firm to discuss their rights. To join the prospective class action, interested parties can visit https://rosenlegal.com/submit-form/?case_id=56641 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com .
The investigation aims to determine if securities laws were violated in connection with the FDA's decision and the subsequent disclosure to the public. The Rosen Law Firm encourages investors to select qualified counsel with a track record of success in leadership roles.
| Event Detail | Description |
|---|---|
| Company | Disc Medicine, Inc. |
| Ticker | IRON |
| Regulatory Body | U.S. Food and Drug Administration (FDA) |
| Program | Bitopertin |
| Action | Complete Response Letter (CRL) |
| Date of CRL | February 13, 2026 |
| Stock Impact | Fell 22% on February 13, 2026 |
What specific additional evidence will the FDA require to address the uncertainties cited in the Complete Response Letter?
How long will it take Disc Medicine to generate and submit the necessary data to resubmit the bitopertin application?
What are the financial implications for Disc Medicine regarding the costs of the new clinical trials or studies required by the FDA?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
